ICON Plc

ICON Plc ICON is a global provider of outsourced clinical research development services to the pharmaceutical, biotechnology, and medical device industries.

We help our clients accelerate the development of life-saving drugs that improve patients' quality of life.

08/09/2025

LabView360 is ICON’s new digital requisitioning application that streamlines end-to-end sample management - eliminating paper requisition forms, reducing errors, and saving valuable time for sites and sponsors.

With digital requisitioning, sites can scan barcodes on samples, capture data in real-time, and ensure greater levels of accuracy – which reduces site burden and time-consuming back and forth on queries. Watch our video to learn more about how this new application will benefit sites and sponsors. https://ow.ly/Jk3L50Vcs8M

Patient voices matter more than ever in obesity research. Join our upcoming webinar to learn how to combine COAs and dig...
08/09/2025

Patient voices matter more than ever in obesity research.
Join our upcoming webinar to learn how to combine COAs and digital health technologies to capture the full patient experience. https://ow.ly/mWIK50WLeLf

Early-stage biotech companies face unique in clinical development. That’s why having partners capable of delivering in...
08/09/2025

Early-stage biotech companies face unique in clinical development. That’s why having partners capable of delivering integrated support - from early development through to trial ex*****on, is crucial.

Read the story of how the fund required flexibility and strategic alignment from the CRO, and how ICON successfully met those needs. https://ow.ly/emwc50WNlJp

Symphony Health, an ICON plc company, are looking forward to Fierce Pharma Week (Sept 8–11) in Philadelphia.Visit us at ...
05/09/2025

Symphony Health, an ICON plc company, are looking forward to Fierce Pharma Week (Sept 8–11) in Philadelphia.

Visit us at booth #1320 to explore how our medical affairs, commercial, and promotional solutions help connect the dots across the patient journey — turning data into evidence, insights, and impact.

https://ow.ly/pcPz50WOVwK

The next in our UK regulatory environment blog series is out now. In this instalment we discuss the opportunity for inte...
05/09/2025

The next in our UK regulatory environment blog series is out now. In this instalment we discuss the opportunity for interactions with both the MHRA and the National Institute for Health and Care Excellence (NICE). These meetings offer drug and medical device developers a strategic alternative when they are unable to access a Joint Scientific Consultation process. Read our blog to understand how https://ow.ly/H1yV50WIHkz

There are many considerations that set oncology biosimilar development apart from that of novel biologics. Read ICON’s a...
05/09/2025

There are many considerations that set oncology biosimilar development apart from that of novel biologics. Read ICON’s article in Drug Discovery & Development magazine to better prepare for challenges such as developing complex modalities, selecting and recruiting patients and encouraging biosimilar adoption. https://ow.ly/1B8X50WQhnI

Clinical data submissions require careful planning, consistency and a strong understanding of agency expectations. This ...
05/09/2025

Clinical data submissions require careful planning, consistency and a strong understanding of agency expectations. This whitepaper explores how regulatory teams can prepare unified materials that meet the requirements of both the FDA and PMDA, while avoiding common pitfalls that lead to delays.

Read the whitepaper for expert insights: https://ow.ly/WMxS50WHE41

Each year, an estimated 400,000 children and adolescents develop cancer. Learn how ICON has been supporting research in ...
04/09/2025

Each year, an estimated 400,000 children and adolescents develop cancer. Learn how ICON has been supporting research in and other diseases. https://ow.ly/VXSx50WOVcN

If your company requires urgent rescue assistance – consider changing CRO. Impossible?Read the full story and learn how ...
04/09/2025

If your company requires urgent rescue assistance – consider changing CRO. Impossible?

Read the full story and learn how the ICON and Sponsor teams had to rapidly prepare for data cuts, while simultaneously transitioning the studies, managing startup processes and dealing with
unknown events, not previously identified by the outgoing CRO under tight timelines. https://ow.ly/M93L50WNlHw

Biotechs and pharma companies in Asia Pacific face rising costs of drug development, depleting R&D pipelines and diminis...
04/09/2025

Biotechs and pharma companies in Asia Pacific face rising costs of drug development, depleting R&D pipelines and diminishing returns on investment.

By joining forces and exploring collaborative R&D partnerships it is possible to overcome these challenges. ICON's Suhail Ali shares considerations on the risks, rewards and path ahead.

Read the article in Biospectrum Asia: https://ow.ly/ZJXB50WQ8S3

Join ICON experts live to learn how integrating COAs and DHTs in obesity trials supports:• Stronger regulatory alignment...
04/09/2025

Join ICON experts live to learn how integrating COAs and DHTs in obesity trials supports:
• Stronger regulatory alignment
• Patient-centered outcomes
• Better trial efficiency

📅 Oct 7 | 11am EDT | https://ow.ly/61yJ50WLeKH

Address

South County Business Park, Leopardstown
Dublin
18

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 8am - 5pm

Telephone

+35312912000

Website

Alerts

Be the first to know and let us send you an email when ICON Plc posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to ICON Plc:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category